• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国接受手术治疗的复发性卵巢透明细胞癌患者的复发模式和生存结果:45例单机构分析

Recurrence Patterns and Survival Outcomes in Chinese Patients with Surgically Treated Recurrent Ovarian Clear Cell Carcinoma: A Single Institutional Analysis of 45 Cases.

作者信息

Ye Shuang, Zhou Shuling, Chen Wei, Xiang Libing, Wu Xiaohua, Yang Huijuan

机构信息

Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.

出版信息

Cancer Manag Res. 2020 Feb 7;12:913-919. doi: 10.2147/CMAR.S242129. eCollection 2020.

DOI:10.2147/CMAR.S242129
PMID:32104073
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7012237/
Abstract

BACKGROUND

To evaluate the recurrence patterns and survival outcomes of surgically treated relapsed ovarian clear cell carcinoma (OCCC) patients.

METHODS

We performed a comprehensive retrospective analysis of all the patients who underwent secondary debulking from 2004/10 to 2019/04.

RESULTS

In total, 45 eligible patients were included. 75.6% of the patients had early-stage disease and platinum-sensitive recurrence accounted for 70.5%. The median progression-free survival after primary surgery (PFS 1) was 20 months (range, 2-137). Of all, 64.4% patients had solitary recurrence and 86.7% patients had no residual disease after secondary surgery. Regarding tumor distribution, the most common site was pelvis (47.5%), followed by lymph node metastases (18.0%) and abdominal wall lesions (8.2%). For the entire population, the median disease-free survival after recurrence (PFS 2) and post-relapse survival (PRS) was 15 months (range, 0-96), and 24 months (range, 3-159), respectively. Eight patients (17.8%) had a prolonged PFS2 more than 30 months. Patients with localized relapse had better survival including PFS 2 (=0.023), PRS (=0.004), and overall survival (OS) (=0.029). Patients who achieved complete resection tended to have longer PFS 2 (=0.017). After multivariate analysis, complete resection at recurrence remained as an independent positive predictor for PFS 2 (=0.022). The median OS was 50 months and was significantly associated with platinum response (=0.003) and number of relapsed lesions (=0.002).

CONCLUSION

A high rate of pelvic recurrence was noted in this population. Patients with focal recurrence had a favorable prognosis. Complete resection at secondary debulking proved to be an independent predictor for disease-free survival.

摘要

背景

评估手术治疗复发卵巢透明细胞癌(OCCC)患者的复发模式和生存结局。

方法

对2004年10月至2019年4月期间接受二次减瘤手术的所有患者进行全面回顾性分析。

结果

共纳入45例符合条件的患者。75.6%的患者为早期疾病,铂敏感复发占70.5%。初次手术后的中位无进展生存期(PFS1)为20个月(范围2 - 137个月)。其中,64.4%的患者为孤立性复发,86.7%的患者二次手术后无残留病灶。关于肿瘤分布,最常见的部位是盆腔(47.5%),其次是淋巴结转移(18.0%)和腹壁病变(8.2%)。对于全体患者,复发后的中位无病生存期(PFS2)和复发后生存期(PRS)分别为15个月(范围0 - 96个月)和24个月(范围3 - 159个月)。8例患者(17.8%)的PFS2延长超过30个月。局部复发的患者生存情况较好,包括PFS2(P = 0.023)、PRS(P = 0.004)和总生存期(OS)(P = 0.029)。实现完全切除的患者PFS2往往更长(P = 0.017)。多因素分析后,复发时的完全切除仍然是PFS2的独立阳性预测因素(P = 0.022)。中位OS为50个月,与铂类反应(P = 0.003)和复发病灶数量(P = 0.002)显著相关。

结论

该人群盆腔复发率较高。局灶性复发的患者预后良好。二次减瘤手术时的完全切除被证明是无病生存期的独立预测因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5127/7012237/142dd5400ae8/CMAR-12-913-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5127/7012237/142dd5400ae8/CMAR-12-913-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5127/7012237/142dd5400ae8/CMAR-12-913-g0001.jpg

相似文献

1
Recurrence Patterns and Survival Outcomes in Chinese Patients with Surgically Treated Recurrent Ovarian Clear Cell Carcinoma: A Single Institutional Analysis of 45 Cases.中国接受手术治疗的复发性卵巢透明细胞癌患者的复发模式和生存结果:45例单机构分析
Cancer Manag Res. 2020 Feb 7;12:913-919. doi: 10.2147/CMAR.S242129. eCollection 2020.
2
Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?复发性上皮性卵巢癌二次细胞减灭术后复发部位是否影响生存?
J Obstet Gynaecol. 2020 Aug;40(6):849-855. doi: 10.1080/01443615.2019.1674264. Epub 2020 Jan 14.
3
Residual Tumor Diameter Predicts Progression After Primary Debulking Surgery of Ovarian Clear Cell Carcinoma (OCCC): Clinicopathologic Study of Stage II-IV OCCC Patients from a Single Institution.残留肿瘤直径可预测卵巢透明细胞癌(OCCC)初次肿瘤细胞减灭术后的进展:来自单一机构的II-IV期OCCC患者的临床病理研究
Cancer Manag Res. 2021 Mar 4;13:2215-2222. doi: 10.2147/CMAR.S293677. eCollection 2021.
4
Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).接受二次减瘤手术加腹腔热灌注化疗(HIPEC)治疗的铂敏感复发性卵巢癌患者的长期生存情况。
Ann Surg Oncol. 2016 May;23(5):1660-5. doi: 10.1245/s10434-015-5050-x. Epub 2015 Dec 29.
5
Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.早期透明细胞卵巢癌辅助铂类化疗三个周期与六个周期的比较——一项多机构队列研究
Gynecol Oncol. 2017 Feb;144(2):274-278. doi: 10.1016/j.ygyno.2016.12.004. Epub 2016 Dec 12.
6
Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.原发晚期或复发性上皮性卵巢癌肿瘤细胞减灭术中的心膈角淋巴结切除术:一项队列研究。
Int J Gynecol Cancer. 2019 Jan;29(1):188-194. doi: 10.1136/ijgc-2018-000073.
7
Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.局限性复发卵巢癌患者:临床结局和预后因素。
Gynecol Oncol. 2013 Oct;131(1):36-41. doi: 10.1016/j.ygyno.2013.06.020. Epub 2013 Jun 20.
8
Patterns of recurrence and impact on survival in patients with clear cell ovarian carcinoma.透明细胞卵巢癌患者的复发模式及其对生存的影响
Int J Gynecol Cancer. 2019 Sep;29(7):1164-1169. doi: 10.1136/ijgc-2019-000287. Epub 2019 Jul 3.
9
Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.纤维蛋白原/白蛋白比值作为预测卵巢透明细胞癌铂类反应和生存的有前途的指标。
BMC Cancer. 2022 Jan 21;22(1):92. doi: 10.1186/s12885-022-09204-0.
10
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.铂敏感复发性卵巢癌中二次细胞减灭术加化疗与单纯化疗的比较(SOC-1):一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2021 Apr;22(4):439-449. doi: 10.1016/S1470-2045(21)00006-1. Epub 2021 Mar 8.

引用本文的文献

1
The added value of chemotherapy after secondary cytoreductive surgery in unifocal versus multifocal first recurrent epithelial ovarian cancer: A systematic review.单灶性与多灶性首次复发上皮性卵巢癌二次减瘤手术后化疗的附加值:一项系统评价。
Gynecol Oncol Rep. 2025 Jul 18;60:101809. doi: 10.1016/j.gore.2025.101809. eCollection 2025 Aug.
2
Molecular subtype of ovarian clear cell carcinoma: an analysis of 80 Chinese patients using the TCGA molecular classification of endometrial cancer.卵巢透明细胞癌的分子亚型:采用子宫内膜癌的TCGA分子分类法对80例中国患者的分析
BMC Cancer. 2025 Jan 15;25(1):90. doi: 10.1186/s12885-024-13389-x.
3

本文引用的文献

1
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.复发性卵巢癌的二次手术细胞减灭术。
N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626.
2
Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?哪些复发性卵巢癌患者能从二次肿瘤细胞减灭术中获益?
J Gynecol Oncol. 2019 Nov;30(6):e116. doi: 10.3802/jgo.2019.30.e116.
3
Patterns of recurrence and impact on survival in patients with clear cell ovarian carcinoma.透明细胞卵巢癌患者的复发模式及其对生存的影响
Clinicopathological factors of ovarian clear cell carcinoma: A single institutional analysis of 247 cases in China.
卵巢透明细胞癌的临床病理因素:中国247例单中心分析
Biomol Biomed. 2025 Jan 14;25(2):436-444. doi: 10.17305/bb.2024.10958.
4
Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report.卵巢透明细胞癌伴 PIK3CA 基因突变的临床分析及文献复习:病例报告。
Medicine (Baltimore). 2022 Sep 16;101(37):e30666. doi: 10.1097/MD.0000000000030666.
5
Integrative genomic and transcriptomic analysis reveals immune subtypes and prognostic markers in ovarian clear cell carcinoma.整合基因组和转录组分析揭示卵巢透明细胞癌的免疫亚型和预后标志物。
Br J Cancer. 2022 May;126(8):1215-1223. doi: 10.1038/s41416-022-01705-w. Epub 2022 Jan 18.
6
Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.卵巢透明细胞癌发病机制、诊断与治疗前景的最新进展
J Cancer. 2021 Feb 22;12(8):2295-2316. doi: 10.7150/jca.53395. eCollection 2021.
Int J Gynecol Cancer. 2019 Sep;29(7):1164-1169. doi: 10.1136/ijgc-2019-000287. Epub 2019 Jul 3.
4
F-FDG PET/CT-based metabolic metrics in recurrent tumors of ovarian clear cell carcinoma and their prognostic implications.基于 F-FDG PET/CT 的代谢指标在卵巢透明细胞癌复发性肿瘤中的应用及其预后意义。
BMC Cancer. 2019 Mar 13;19(1):226. doi: 10.1186/s12885-019-5441-7.
5
Oncologic outcomes after secondary surgery in recurrent clear-cell carcinoma of the ovary.复发性卵巢透明细胞癌二次手术后的肿瘤学结局。
Int J Gynecol Cancer. 2019 Jun;29(5):910-915. doi: 10.1136/ijgc-2018-000142. Epub 2019 Mar 5.
6
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.口服 ENMD-2076 治疗卵巢透明细胞癌的临床和分子 II 期试验:玛格丽特公主癌症中心 II 期联盟研究。
Clin Cancer Res. 2018 Dec 15;24(24):6168-6174. doi: 10.1158/1078-0432.CCR-18-1244. Epub 2018 Aug 14.
7
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).一项舒尼替尼治疗持续性或复发性透明细胞卵巢癌的 II 期评估:NRG 肿瘤学/妇科肿瘤学组研究(GOG-254)。
Gynecol Oncol. 2018 Aug;150(2):247-252. doi: 10.1016/j.ygyno.2018.05.029. Epub 2018 Jun 18.
8
When should Surgery be used for Recurrent Ovarian Carcinoma?复发性卵巢癌何时应采用手术治疗?
Clin Oncol (R Coll Radiol). 2018 Aug;30(8):493-497. doi: 10.1016/j.clon.2018.04.006. Epub 2018 May 7.
9
Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).卡博替尼单药治疗复发性透明细胞卵巢癌、原发性腹膜癌或输卵管癌患者的 II 期研究(NRG-GY001)。
Gynecol Oncol. 2018 Jul;150(1):9-13. doi: 10.1016/j.ygyno.2018.04.572. Epub 2018 May 5.
10
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.贝伐珠单抗联合紫杉醇-卡铂化疗和二次细胞减灭术治疗复发性铂敏感型卵巢癌(NRG 肿瘤学/妇科肿瘤学组研究 GOG-0213):一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2017 Jun;18(6):779-791. doi: 10.1016/S1470-2045(17)30279-6. Epub 2017 Apr 21.